Pharsight

Savaysa generic

Savaysa is a drug owned by Daiichi Sankyo Inc., and contains the active ingredient edoxaban tosylate. The drug received authorization for market use on 08 January, 2015, and it comes in tablet form for oral administration. Savaysa currently has two valid patents, none of which have expired so far.

When will Savaysa generic be available?

The Savaysa generic is expected to be released after the expiry of its last patent, which will occur on 28 March 2028. This is not due to a Para IV filing, but to the expiration of the drug's patent life.

Savaysa uses

Savaysa, containing edoxaban tosylate as its active ingredient, is primarily used in preventing deep vein thrombosis, which can lead to blood clots in the body. This drug is also used to reduce the risk of stroke and blood clots in individuals that have a certain type of heart rhythm disorder.

Savaysa patent expiration

Savaysa, owned by Daiichi Sankyo Inc., has a total of two patents. The last patent is set to expire on 28 March 2028, making the Savaysa generic available post this date. Below are the details of the patents:

EPO Oppostions filed on Savaysa

Savaysa dosage

Want to ask something?